The impact of mitochondrial topoisomerase I expression in head and neck squamous cell carcinoma

doi:10.19438/j.cjoms.2023.05.003

Abstract

Abstract: PURPOSE: To analyze the correlation between mitochondrial topoisomerase I (TOP1MT) and the clinicopathological characteristics of head and neck squamous cell carcinoma(HNSCC), and to explore its impact on cisplatin resistance in HNSCC. METHODS: The correlation between TOP1MT and clinicopathological characteristics was analyzed by combining the information of 83 clinical patients with the results of immunohistochemical staining and real-time fluorescence quantitative PCR(qRT-PCR). The effect of TOP1MT on proliferation and migration of HNSCC cells with cisplatin treatment was analyzed by in vitro experiments. SPSS 26.0 software package was used for statistical analysis. RESULTS: High expressed TOP1MT was related to tumor size, clinical stage, overall survival, efficacy of TPF regimen, and worse prognosis of HNSCC patients, and the survival probability of patients with high expression of TOP1MT was significantly lower than that of patients with moderate and low expression. In vitro experiments showed that overexpression of TOP1MT significantly promoted the migration and proliferation of HNSCC cells HN30 and HN4 with 20 μmol/L cisplatin treatment. CONCLUSIONS: High expression of TOP1MT in HNSCC indicates insensitivity to chemotherapy and decreased overall survival. The experiment confirmed that TOP1MT promotes HNSCC development and may act as a potential target for clinical therapy.

Key words: TOP1MT, Head and neck squamous cell carcinoma, Cisplatin, Chemoresistance

CLC Number:

R739.8

ZHAI Pei-song, TONG Tong, LIU Chun, MA Hai-long, ZHANG Jian-jun. The impact of mitochondrial topoisomerase I expression in head and neck squamous cell carcinoma[J]. China Journal of Oral and Maxillofacial Surgery, 2023, 21(5): 439-445.

References

[1] Solomon B, Young RJ, Rischin D.Head and neck squamous cell carcinoma: genomics and emerging biomarkers for immunomodulatory cancer treatments[J]. Semin Cancer Biol, 2018, 52(2): 228-240.
[2] Smith CD, Carmeli S, Moore RE, et al.Scytophycins, novel microfilament-depolymerizing agents which circumvent P-glycoprotein-mediated multidrug resistance[J]. Cancer Res, 1993, 53(6): 1343-1347.
[3] Sakamoto M, Kondo A, Kawasaki K, et al.Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray[J]. Human Cell, 2001, 14(4): 305-315.
[4] Kasahara K, Fujiwara Y, Nishio K, et al.Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin[J]. Cancer Res, 1991,51(12):3237-3242.
[5] Chaney SG, Sancar A.DNA repair: enzymatic mechanisms and relevance to drug response[J]. J Natl Cancer Inst, 1996, 88(19):1346-1360.
[6] Vousden KH, Lane DP.P53 in health and disease[J]. Nat Rev Mol Cell Biol, 2007, 8(4): 275-283.
[7] Hengstler JG, Pilch H, Schmidt M, et al.Metallothionein expression in ovarian cancer in relation to histopathological parameters and molecular markers of prognosis[J]. Int J Cancer, 2001, 95(2): 121-127.
[8] Tong T, Qin X, Jiang Y, et al.A novel CREB5/TOP1MT axis confers cisplatin resistance through inhibiting mitochondrial apoptosis in head and neck squamous cell carcinoma[J]. BMC Med, 2022, 20(1):1-21.
[9] Lee NCJ, Kelly JR, Park HS, et al.Patterns of failure in high-metastatic node number human papillomavirus-positive oropharyngeal carcinoma[J]. Oral Oncol, 2018, 85: 35-39.
[10] Theile D, Ketabi-Kiyanvash N, Herold-Mende C, et al.Evaluation of drug transporters’ significance for multidrug resistance in head and neck squamous cell carcinoma[J]. Head and Neck, 2011, 33(7): 959-968.
[11] Galluzzi L, Senovilla L, Vitale I, et al.Molecular mechanisms of cisplatin resistance[J]. Oncogene, 2012, 31(15): 1869-1883.
[12] Pommier Y, Nussenzweig A, Takeda S, et al.Human topoisomerases and their roles in genome stability and organization[J]. Nat Rev Mol Cell Biol, 2022, 23(6): 407-427.
[13] Baechler SA, Factor VM, Rosa ID, et al.The mitochondrial type IB topoisomerase drives mitochondrial translation and carcinogenesis[J]. Nat Commun, 2019, 10(1): 1-13.
[14] Stewart L, Stewart L, Redinbo MR, et al.A model for the mechanism of human topoisomerase I[J]. Science, 1998, 279(5356): 1534-1541.
[15] Fei L, Lu Z, Xu Y, et al.A comprehensive pan-cancer analysis of the expression characteristics, prognostic value, and immune characteristics of TOP1MT[J]. Front Genet, 2022, 13: 920897.
[16] Zoppoli G, Douarre C, Rosa ID, et al.Coordinated regulation of mitochondrial topoisomerase IB with mitochondrial nuclear encoded genes and MYC[J]. Nucleic Acids Res, 2011, 39(15): 6620-6632.
[17] Khiati S, Rosa ID, Sourbier C, et al.Mitochondrial topoisomerase I ( Top1mt ) is a novel limiting factor of doxorubicin cardiotoxicity[J]. Clin Cancer Res, 2014, 20(18): 4873-4881.
[18] Lu Q, Wang M, Gui Y, et al.Rheb1 protects against cisplatin-induced tubular cell death and acute kidney injury via maintaining mitochondrial homeostasis[J]. Cell Death Dis, 2020, 11(5): 364-378.
[19] Yu X, Meng X, Xu M, et al.Celastrol ameliorates cisplatin nephrotoxicity by inhibiting NF-κB and improving mitochondrial function[J]. EBioMedicine, 2018, 36: 266-280.
[20] Gong W, Lu L, Zhou Y, et al.The novel STING antagonist H151 ameliorates cisplatin-induced acute kidney injury and mitochondrial dysfunction[J]. Am J Physiol Renal Physiol, 2021, 320(4): F608-F616.
[21] Bajwa A, Rosin DL, Chroscicki P, et al.Sphingosine 1-phosphate receptor-1 enhances mitochondrial function and reduces cisplatin-induced tubule injury[J]. J Am Soc Nephrol, 2015, 26(4): 908-925.
[22] Kohno K, Wang KY, Takahashi M, et al.Mitochondrial transcription factor a and mitochondrial genome as molecular targets for cisplatin-based cancer chemotherapy[J]. Int J Mol Sci, 2015, 16(8): 19836-19850.